Eli Lilly and (LLY) Revenue — Quarter Ended Dec 31, 2024
Revenue increased for the quarter. Growth was strong compared to both the prior quarter and the same period last year.
Key takeaway
Quarter ended Dec 31, 2024 · FY2024 Q4
Revenue increased for the quarter. Growth was strong compared to both the prior quarter and the same period last year.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$13.5B
Revenue reported for this quarter.
Quarter-over-quarter
+18.3%
Change from the immediately preceding quarter.
Year-over-year
+44.7%
Change from the comparable year-ago quarter.
Trailing four quarters
$45B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2024 | $8.8B | +26.0% |
| Jun 30, 2024 | $11.3B | +36.0% |
| Sep 30, 2024 | $11.4B | +20.4% |
| Dec 31, 2024 | $13.5B | +44.7% |
Revenue performance
The company reported higher revenue for the period, continuing a trend of sequential growth.
Quarterly comparison
Revenue rose from the immediately preceding quarter and was substantially above the level seen a year earlier.
What to watch
The company faces significant contractual commitments for manufacturing capacity expansion, particularly related to its incretin medicines.